Knowledge base · Peer-reviewed

ScaleWiki.

Peer-reviewed manuscripts on the G-Rex® platform — one citable page per paper, curated so you find the evidence that moves your cell & gene therapy program forward.

487Manuscripts indexed
14Cell types
Live indexContinuously updated

Showing 12 of 530 resources

Publications VST Cells G-Rex®10

Publication Date: January 18, 2021

“Cerberus” T Cells: A Glucocorticoid-Resistant, Multi-Pathogen Specific T Cell Product to Fight Infections in Severely Immunocompromised Patients

A single T-cell product simultaneously specific for four viruses (adenovirus, cytomegalovirus, Epstein-Barr virus and BK virus) and for Aspergillus fumigatus kept working in the presence of high-dose glucocorticoids after CRISPR/Cas9 disruption of the glucocorticoid receptor. Starting from 4.5 x 10^7 peripheral blood mononuclear cells drawn from 35 ml of donor blood, cells were pulsed with viral and fungal peptides, electroporated on day 3 with Cas9 ribonucleoproteins carrying the e2b guide RNA, and harvested after a 10-day culture, yielding on average 1.94 ± 0.5 x 10^8 cells. On-target cleavage averaged 21.4 ± 2.2% and 25.7 ± 2.6% of cells were receptor-negative. Edited cells retained me…

Download Now →

Author: Kiriakos Koukoulias, Penelope-Georgia Papayanni +14 more

Publications VST Cells G-Rex®100M-CS

Publication Date: January 8, 2021

Rapid GMP-Compliant Expansion of SARS-CoV-2–Specific T Cells From Convalescent Donors for Use as an Allogeneic Cell Therapy for COVID-19

Virus-specific T cells for COVID-19 can be isolated from convalescent blood donations and expanded under GMP-compliant conditions to numbers sufficient for multiple allogeneic doses. Buffy coats from 15 convalescent donors, collected 34 to 56 days after symptom resolution, contained CD4 and CD8 memory T cells reactive to spike, nucleocapsid and membrane peptides. Cells secreting IFN-γ after peptide stimulation were captured, fed with irradiated non-target cells and expanded in G-Rex® vessels. After 14 days cultures were 87.95% T cells, mostly central memory CD4 cells, with yields of 1 to 4.6 × 10^9 cells; a second feeder stimulation gave 0.3 to 2 × 10^11 cells at day 21. Two leukapheresis…

Download Now →

Author: Rachel S. Cooper, Alasdair R. Fraser +8 more

Publications TIL Cells G-Rex®6 Well Plate, G-Rex®6M Well Plate

Publication Date: January 1, 2021

High-dose TIL product with improved phenotype and functionality

Changing the initial culture conditions of tumor-infiltrating lymphocyte (TIL) expansion shortened production to about three weeks and gave a TIL product rich in functional CD8+ T cells. TILs were grown from fresh and frozen tumor fragments of patients with various solid tumors in G-Rex® vessels with high-dose IL-2 and TIL stimulators, and compared with the standard 24-well plate protocol that takes 4 to 7 weeks. Culture success, defined as reaching 100,000 cells per fragment within four weeks, was 95.8% and 81.8% in the two stimulator conditions versus 33.3% with IL-2 alone. Both conditions favored CD8+ T-cell expansion. A subsequent rapid expansion in G-Rex® 6-well plates reached a mean…

Download Now →

Author: Christina Friese, Christina Heeke +5 more

Publications CAR T Cells

Publication Date: December 24, 2020

Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves anti-tumor efficacy when combined with checkpoint blockade

In an autochthonous Kras-p53 mouse model of lung adenocarcinoma engineered to express human ROR1, ROR1 CAR-T cells given after cyclophosphamide lymphodepletion reduced tumor growth for only six weeks, all tumors eventually progressed, and more than half of tumor nodules were devoid of T cells. Adding oxaliplatin to the lymphodepletion regimen altered expression of 418 genes in lung tumors and activated iNOS+ macrophages that supplied Cxcl9, Cxcl10, Ccl5 and Cxcl16, significantly increasing CAR-T cell accumulation in tumors but not spleens by day 10. Early infiltration depended partly on CXCR6 and CCR5 and later infiltration on CXCR3. Oxaliplatin plus cyclophosphamide alone did not improve…

Download Now →

Author: Shivani Srivastava, Scott N. Furlan +18 more

Publications CAR T Cells, TCR T Cells G-Rex®24 Well Plate

Publication Date: December 4, 2020

Re-examination of MAGE-A3 as a T-cell Therapeutic Target

Testing of the MAGE-A12 cross-reactivity hypothesis for the neurotoxicity that halted a clinical MAGE-A3 TCR-T found no rare MAGE-A12 high-expressing cells in the brain, and pointed instead to a homologous EPS8L2 peptide. RNA FISH across about 3.2 million brain cells from 8 postmortem donors detected only a single cell with multiple dots. Public RNA-Seq showed MAGE-A12 at most 0.3 TPM in basal ganglia, while EPS8L2 reached 64 TPM in cerebellum. The A118T TCR killed HLA-A*02-expressing CAPAN-2 cells, which express EPS8L2 but not MAGE-A3 or -A12. Two newly isolated MAGE-A3 pMHC-directed CARs discriminated better against EPS8L2, the MAGE-A3112-120 CAR showing no detectable primary T-cell act…

Download Now →

Author: Aaron D. Martin, Xueyin Wang +10 more

Publications CAR T Cells

Publication Date: November 22, 2020

Autologous non-human primate model for safety assessment of piggyBac transposon-mediated chimeric antigen receptor T cells on granulocyte–macrophage colony-stimulating factor receptor

Cynomolgus macaque T cells engineered with a piggyBac transposon to carry a CAR directed at the GM-CSF receptor (hGMR) caused no overt organ toxicity when returned to the same animals. Six macaques were used: three received autologous hGMR-CAR T cells at 3 × 10^5 CAR+ cells per kg and three received control T cells. Although the CAR T cells killed cynomolgus monocytes and M1 macrophages in vitro, monocyte counts, blood counts, coagulation values and tissue pathology showed no CAR-related damage over 14 days. The transgene fell to undetectable levels within a week, and IL-6 rose only transiently and mildly in one animal without symptoms of cytokine release syndrome.

Download Now →

Author: Hirokazu Morokawa, Shigeki Yagyu +7 more

Publications VST Cells G-Rex®10M

Publication Date: November 20, 2020

Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients

Virus-specific T cells directed against BK polyomavirus produced antiviral responses with minimal toxicity in transplant recipients in a phase 2 trial. Between June 2017 and December 2019, 38 stem cell transplant recipients and 3 solid organ transplant recipients were treated with donor-derived or third-party T cells, manufactured from donor blood in 11 to 12 days. Overall response was 86% for BK viremia, 100% for hemorrhagic cystitis and 87% for both conditions. Response per infusion for viremia was 95% with third-party and 75% with donor-derived products. No infusion reactions, de novo graft-versus-host disease or graft rejection were attributed to the infusions. Among responders with a…

Download Now →

Author: Adam S. Nelson, Daria Heyenbruch +13 more

Publications T-Cells G-Rex®24 Well Plate

Publication Date: November 19, 2020

A soluble activator that favors the ex vivo expansion of CD8+CD27+ T cells

A small soluble bispecific protein that binds both CD3 and CD28, called T-CEP, expanded human T cells ex vivo at femtomolar concentrations and skewed the product toward CD8+ cells with a less differentiated CD27+ phenotype. Used at 10 ng/mL (170 fM) with IL-2 over 12 days, it was about 150-fold lower in mass concentration than a commercial tetrameric antibody complex activator. Across five healthy donors, CD8+ T cells expanded a mean of 317-fold, and CD8+CD27+ cells expanded 325-fold, the highest in every donor. CD8+CD27+ cells made up a mean of 62.3% of viable lymphocytes on day 12, versus 34.3% to 38.1% with the other methods tested.

Download Now →

Author: Esther I. Matus, Amanda Sparkes +1 more

Publications Other

Publication Date: November 16, 2020

AIM Platform: A Novel Nano Artificial Antigen-Presenting Cell-Based Clinical System Designed to Consistently Produce Multi-Antigen-Specific T-Cell Products with Potent and Durable Anti-Tumor Properties

A nanoparticle-based artificial antigen-presenting cell system, combined with a semi-automated enrichment and expansion process, produces multi-antigen-specific CD8+ T-cell products from the endogenous repertoire without genetic engineering. Superparamagnetic iron-oxide AIM nanoparticles carry HLA-A2 dimers and anti-CD28 antibody, are loaded with tumor peptides, and magnetically enrich antigen-specific cells from a leukopak after CD4+ depletion. Cells are then expanded for 14 days. In AML examples using five peptides, products averaged more than 20% antigen-specific cells, about 60% of cells showed 3–4 effector functions, and roughly 90% were Tscm, Tcm or Tem cells. Two phase 1/2 trials i…

Download Now →

Author: Lauren Suarez, Ruipeng Wang +5 more

Publications CAR T Cells

Publication Date: November 9, 2020

Preclinical Validation and Manufacture of IL-8 Receptor-Modified CD70 CAR T Cells for Clinical Trial

Interleukin-8 receptor-linked CD70 CAR T cells (8R-70CAR) showed a favorable safety and manufacturing profile in preclinical work supporting a planned phase I glioblastoma trial. In C57BL/6J mice irradiated with 5 Gy and given 2 × 10^6 mouse 8R-70CAR T cells intravenously, no CAR T cell-related toxicity was observed, based on body weight, clinical signs, hematology, serum chemistry, cytokines and pathology of 12 vital organs. Human 8R-70CAR T cells made from glioblastoma patients' T cells were reactive against CD70-positive glioblastoma, measured by interferon-gamma production. They also expanded more than other CAR T cells tested, about 1200-fold over two weeks of production in the G-Rex…

Download Now →

Author: Linchun Jin, Haipeng Tao +8 more

Publications CAR T Cells, TCR T Cells G-Rex®24 Well Plate

Publication Date: November 9, 2020

A multivariate, quantitative assay that disentangles key kinetic parameters of primary human T cell function in vitro

The Quantitative Imaging-based Killing (QuIK) assay tracks primary human CAR-T and TCR-T cells cocultured with peptide-loaded A375 target cells in an IncuCyte imager. It separates antigen-dependent T cell proliferation from specific killing over time, using three dyes and per-cell rate calculations. Three HPV-directed receptors were compared at E:T ratios of 3:1, 1:1 and 1:3. Proliferation peaked at 72 hours and killing at 48 hours. The maximum kill rate occurred at about 24 hours for all constructs. Maximum killing fell at lower E:T ratios, while T cells proliferated more when cytotoxicity was lower. The HPV E7 CAR showed neither specific killing nor proliferation and had high tonic acti…

Download Now →

Author: Grace L. Huang, Daniel P. Nampe +5 more

Publications VST Cells

Publication Date: November 5, 2020

Using Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High Risk Patients with COVID-19

Virus-specific T cells generated from convalescent donors with mild COVID-19 selectively killed targets expressing SARS-CoV-2 antigens, supporting a banked, off-the-shelf product for high-risk patients. Donor cells were screened against peptide libraries covering 18 viral proteins, and eight immunodominant targets were chosen for manufacturing in a G-Rex® device with activating cytokines. Cells expanded a mean 29-fold (n=5) and were 97.1% CD3+, mostly CD4+ helper (85.5%) with 10.2% CD8+. All lines responded to the target antigens by IFNγ ELISpot, were Th1-polarized, and killed pepmix-loaded autologous PHA blasts without auto- or alloreactivity. The authors are advancing the product toward…

Download Now →

Author: Spyridoula Vasileiou, Manik Kuvalekar +11 more